Nyrada Inc. (NYR.AX)

AUD 0.1

(-2.0%)

Market Cap (In AUD)

19.64 Million

Revenue (In AUD)

-

Net Income (In AUD)

-1.38 Million

Avg. Volume

325.1 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.018-0.17
PE
-
EPS
-
Beta Value
1.087
ISIN
AU0000070195
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. James Bonnar
Employee Count
-
Website
https://www.nyrada.com
Ipo Date
2020-01-15
Details
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in the drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; a neuroprotectant drug to reduce the disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. The company has collaboration with Walter Reed Army Institute of Research and University of New South Wales, Sydney. Nyrada Inc. was incorporated in 2017 and is based in Gordon, Australia.